Charles A. Rowland Jr. serves as
Independent Director of the Company. He has served as a member of our board of directors since March 2015. From April 2016 to February 2017, Mr. Rowland served as president and chief executive officer of Aurinia Pharmaceuticals Inc., or Aurinia, and as a member of the board of directors of Aurinia from July 2014 to February 2017. Mr. Rowland previously served as vice president and chief financial officer of ViroPharma Incorporated, or ViroPharma, an international biopharmaceutical company, from October 2008 until it was acquired by Shire plc in January 2014. Prior to joining ViroPharma, from 2006 to 2008, Mr. Rowland served as executive vice president and chief financial officer, as well as the interim co-chief executive officer, for Endo Pharmaceuticals Inc., a specialty pharmaceutical company with a primary focus in pain management. Mr. Rowland previously held positions of increasing responsibility at the following biopharmaceutical companies: Biovail Pharmaceuticals, Inc., Breakaway Technologies, Inc., Pharmacia Corporation, Novartis AG and Bristol-Myers Squibb Co. Mr. Rowland has served as a member of the board of directors and chairman of the audit committee and compensation committee of Orchard Therapeutics plc since June 2018, as a member of the board of directors, chairman of the compensation committee and member of the audit committee of Viking Therapeutics, Inc. since July 2017 and as a member of the board of directors and chairman of the audit committee and compensation committee of Nabriva Therapeutics, AG, a biotechnology company based in Dublin, Ireland, since January 2015. In addition, Mr. Rowland currently serves on the board of directors and as chairman of the audit committee of Generation Bio, a privately held biopharmaceutical company. Mr. Rowland served as a member of the board of directors and audit committee of Idenix Pharmaceuticals, Inc., a biopharmaceutical company, from June 2013 it was acquired by Merck & Co., Inc. in August 2014.
What is Charles A. Rowland, Jr.'s net worth?
The estimated net worth of Charles A. Rowland, Jr. is at least $2.70 million as of May 16th, 2023. Mr. Rowland, Jr. owns 30,000 shares of Blueprint Medicines stock worth more than $2,700,300 as of April 3rd. This net worth evaluation does not reflect any other investments that Mr. Rowland, Jr. may own. Learn More about Charles A. Rowland, Jr.'s net worth.
How do I contact Charles A. Rowland, Jr.?
The corporate mailing address for Mr. Rowland, Jr. and other Blueprint Medicines executives is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. Blueprint Medicines can also be reached via phone at (617) 374-7580 and via email at ir@blueprintmedicines.com. Learn More on Charles A. Rowland, Jr.'s contact information.
Has Charles A. Rowland, Jr. been buying or selling shares of Blueprint Medicines?
Charles A. Rowland, Jr. has not been actively trading shares of Blueprint Medicines over the course of the past ninety days. Most recently, Charles A. Rowland, Jr. sold 10,909 shares of the business's stock in a transaction on Thursday, December 17th. The shares were sold at an average price of $117.82, for a transaction totalling $1,285,298.38. Following the completion of the sale, the director now directly owns 14,471 shares of the company's stock, valued at $1,704,973.22. Learn More on Charles A. Rowland, Jr.'s trading history.
Who are Blueprint Medicines' active insiders?
Blueprint Medicines' insider roster includes Jeffrey Albers (CEO), Percy Carter (Insider), George Demetri (Director), Debra Durso-Bumpus (Insider), Mark Goldberg (Director), Kate Haviland (President, CEO & Director), L. Hewes (Insider), Ariel Hurley (Insider), Michael Landsittel (CFO), Philina Lee (Insider), Nicholas Lydon (Director), Tracey Mccain (EVP), Christopher Murray (Insider), Fouad Namouni (Insider), Christina Rossi (Insider), and Charles Rowland, Jr. (Director). Learn More on Blueprint Medicines' active insiders.
Are insiders buying or selling shares of Blueprint Medicines?
In the last twelve months, insiders at the biotechnology company sold shares 23 times. They sold a total of 242,772 shares worth more than $24,685,047.58. The most recent insider tranaction occured on March, 24th when COO Christina Rossi sold 2,274 shares worth more than $216,075.48. Insiders at Blueprint Medicines own 4.2% of the company.
Learn More about insider trades at Blueprint Medicines. Information on this page was last updated on 3/24/2025.
